I NTROD UCTION
Though a comparison of current clinical psychopharmacol ogica l practi ces in France and the u.s. is an unaddressed topic, these co n trasts may be quite striking to an American-trained psychiatrist. The following observations are based on my two month inpatient experience as a fourth-year psych iatr ic resident at a public psychiatric institution located in Montpelli er, Fran ce (1987) . This article was written in collaboration with Dr. Blayac who is o ne of th e regional center directors for the Fr ench equivalent of th e FD A .
Before I begin to discu ss this topic, I think th at th e reader should be mad e aware o f some fund am ental differences between French a nd A merican psychi atry. Fren ch psychiatry is an integral part of a socialized fo r m of med icine, whi ch helps one understand th e socioeco no m ic setting in whi ch French psych op har macology is practiced as well as these practices' financial co ns tra in ts. This may a lso co n tr ib u te to the practical pharmacological orientation one observes in a public setting, even where a psychodynamic orientation is very often th eo ret ica lly proposed. An additional difference is that the Fr ench public sec to r combines acad e m ic a nd community psychiatry syno ny mous ly. This does no t appear to ha ve much bearing on psychopharmacol ogi cal practi ce.
T h is a r ticle intends to aler t th e reader to a different sp here of psych opha rma col ogical practi ces wh ich may help th e A mer ica n cli nician reassess what T he author wo uld like to ac knowledge th e fo llowi ng pe rsons: Carlos Mun iz, M.D., Marijan H erj anic, M.D. , Lindsay DeVan e , Ph arm D. 3 he/she is doing presently in this cou ntry . Let me sim p ly state that none of the following different practices are absolutely or uni forml y foll o wed in France but th at the ba sic tendencies and mode of practice are co nsis tent with what is currentl y considered acceptable in French ps ychiatry.
Therefore, in order to better understand the differences (Table 1) between psychopharmacological practices in France and th e U .S., I will firs t consider their similarities.
SIMILARITIES
The similarities between the U.S. and France with r esp ect to psych o p har maco lo gica l practice reflect certain general universal guideli nes of treat me n t. Antipsychotics are primarily indicated for ps ychoses. Lithium t herapy is the first line drug in the prophylactic treatment of bipolar di sorder. A n tidepressants including polycyclic antidepressants and MAO inhibitors a re indicat ed for major depression and relatively contraindicated in psychotic and bipol ar di sord ers ( 1). Antianxiety agents including benzodiazepines, antihistamines, propaned iols and barbiturates, are used to treat anxiety and sleep di sorders.
DIFFERENCES

N euroleptic Treatment
In the United States, one ca n say that it is a fairl y common p ractice to place an acutely psychotic individual o n one neuroleptic at a time (2), wh ose reasonabl e trial extends to a minimum o f two or more weeks d e pe nd ing on the severity (2) . Mo st recently, benzodiazepines with short half-lives (i.e. Lorazepam) are sometimes combined with neuroleptics during initia l tr eatme nt (3, 4) . It should be noted at this point that in th e United Stat es co nsideration of possible late onset tardive dyskinesia is commonly present in th e clinician's mind when he prescribes neuroleptics, in part because o f its forensic co nsequences (5).
On inpatient psychiatric units in France , it is quite co m mon to treat schizophrenic patients concomitantly with two neuroleptics; th ere is us ua lly one high potency neuroleptic such as Haloperidol, at doses ranging from 30 to 40 mg per day, com bined with relatively lower doses (under 150 mg per day) of a lo w potency neuroleptic such as chlorpromazine (6) . T he sedati ng low potency neuroleptic is used for its tranquilizing effect. T ardi ve d yskinesia is a consideration; however, the legal implications are not a determinant o r a d et erre nt in the evaluation of the medication's risks. T he rationale for combi ning the two different classes of neuroleptics are the following: a) Historically this mode of prescription dates back many years and is co nsid er ed fairly conventional b y both psychopharmacologists and clinical practitioners, although this association was studied in th e 1960's and considered by man y American authors such as Freeman (7) to be no m o re effective than monotherapy throughout the treatment's duration.
b) The anticholinergic effects of the low-potency neurol eptic decreases the e x tr apyr a m ida l side effects ofthe high-potency neuroleptic. The result is thought to produce a decreased ins tance of secondary side effect s (8) ; o ther anticholinergic medica tions are, therefore, less necessary. This d oes not im p ly, h owe ve r , that one never sees anticholinergic medications prescribed in association with high -potency neuroleptics. The latter brings us to the co n t in ui ng deba te over whether or no t to com bine antichol inergic medications with high-po te ncy neuroleptics for prophylaxis of extrapyramidal side effects. This d ebate is ac tive on both sides of the Atlantic (2 ,6). Here, le t me note that sim ilar an tich o line r gic medica tions exist in bo t h countries, but p rescribing patterns diffe r (Table 1) . For exa mple, benztrop in e is rarely used in France; while bipe riden , wh ich h as a shorter halfl ife is co m mon ly used in France, in both oral and depot forms (9, 10) . T he ulti mate effec t is the same bu t t he choice of drug is com mo n ly based mor e o n com merc ia l factors .
A nother im portant note tha t must be made concerning the trea tme nt of ot her side-e ffec ts secondary to neurol eptics, refers to orthostatic h ypotension . In Fran ce this is syste matica lly treate d b y a sym pathomimetic drug known as h eptam inol (6) . Phenyleph ri ne , p rese nts this ind ication in France but is not used fo r t h is purpose in curren t common U .S. cli nica l psychiatric inpatient practi ce . In t he U .S. , p atie nts are first advised to r ise slow ly from a sitting positi o n; su pport h o se o r stoc kings are a lso so meti mes suggested. Often the drug ma y be discontinued . IV in fu sio n of a vasopressor agent, such as norepinephrin e , may be recom mended t heoretically only in severe cas es (2), gi ven that postu ral h yp ote nsio n usu all y occurs only during the first few days o f treatment a nd is not ord inarily troublesome when t he dose is given orally.
In the Uni te d Sta tes t he depot forms of neuroleptics are commonl y used . T he flu p henazine deca noa te dosage usu ally ranges from 25 mg to 50 mg 1M every two weeks. Most recently, hal ope r id o l d eca noa te ha s been ma rk eted in th is country a nd the initial maxi mum d ose is 10 0 mg 1M every four weeks.
In France, d epo t neurolep tics ha ve bee n used for many yea rs. No t only do they ha ve hal operid ol and fluph enazin e in this pharmaceutical preparati on but t hey a lso use d epo t fo r ms of other p iperazi ne or piperidine phenothiazin es (p ipotiaz ine a n d pe rph ena zin e) as we ll as the depot form of the thi ox anth in e flupentixol (11) . Hi gh e r d oses of d ecanoat e a re usually prescribed, su ch as 100 to 30 0 mg 1M o f h aloperid ol d ecan oate every fo u r weeks, and 25-100 mg 1M o f fluph enazine d ecanoate every three weeks. Interestin gl y, decanoates are a lso indica te d in lo we r d oses for adolescent co nd uct d isorders. I noted this clini cal psychop har macological pract ice wh ile wo r ki ng in France; I was not, howe ve r , ab le to fin d j us tificatio n for t h is p ractice in any of the literature. The ra t io na le given behind th is indica tion was that ma n y of t hese adolescents are consid ered laten t schizophrenics . G iven th e ir poor compliance with medication s as well as t he need for beha vioral co ntrol of this anger prone population , th e use of low-dose depot neuroleptics is thought to be quite helpful therapeut icall y for t hese pa tie nts. It is pa r ticula rl y interesting to note that in th e Unite d States, these sa me ad o lesce nts would most likely be gi ven a tria l of a tricyclic antidepressant.
In France, the frequent use of th e butyrophenone d rope ri d ol for prompt control of psychotic agitation (6) is al so notable, though in the Un ited States it is used only as a pre-anesthetic medication (10) . The doses used in the United States are lower (10) than those used in France . In practice , it is admin istered intramuscularly. Theoretically it may be given intravenously.
Finall y, and most importantl y, it sho u ld be noted that th ere exists in France a n entire cla ss of neuroleptics, call ed su bstitu te d benzamides (I I ). Metoclopramide is the onl y subs titu ted benzamide a vailable in th e U nited States however , a nd is approved only for treatment of gastrointestinal di sorde rs (10) . Su lpiride an d su ltoprid e, which have existed for many yea rs in Eu r ope, a re no t available in the United States. The rea son given for the non-approval o f th ese drugs is th at there is co nce r n about long term toxicity, that the y increa se p r olactin secretion to a higher degree than classical neuroleptics and that th ei r su perior antipsychotic effect is debatable. The literature has sh own tha t th ese agents are effective antipsychotic drugs (12 , I 3). It is sig n ifica n t that in Fra nce bromocriptin e is sometimes associated with sulpi ride as a proph ylaxis against galactorrhea (5), just as benztropine is associated prophylacti call y with halope r id o l in the event of e x trapy r a m ida l side effects. Carpipramine represents another class of a n tipsy chotic wh ich has been co m mercialized in Fran ce since 197 7 ( 14) ; it has a ntidep ressa nt properties like su lp iri de (6).
Lithium Therapy
There are not too many French/U .S. differences co ncern ing th e use a nd indications for lithium therapy. French clinicians a re reluct ant to use lit h iu m for an ything other than its primary indication of bipolar dis o rder. Becau se of the required biological su r veillances, the latter is es pecially tr ue in t he p ublic sector where compliance is questi onable , a nd fin ancial cost a considera tion. As for alternat e treatments, it can be no ted th at carba mazep ine trials are rather recent in Fran ce (five yea rs) . Howe ve r , va lprom ide, wh ich is chemica lly related to va lpro ic ac id, h as b een formall y recogn ize d and co m merc ia lized in Fra n ce since 197 I ( 14) as an alternate when lithium is co ntrain d ica te d (I 1,1 5).
Antidepressants
MAO inhibitors are sel dom p rescribed in France (16) . There are sev eral e xp la na tio ns for thei r pro scriptio n. Wine and cheese are an integral part of all meal s in Fra nce which mak es the use of MAOI 's ra ther difficu lt even though it is recognized th at o n ly 20 % or less of pa t ients ma y de vel op a h ypertensive crisis o n a tyr am in e-containing di et. Howe ve r , t he main reaso n for the proscription o f th ese drugs is that psychiatrists are se r io us ly di scou raged by anesthesiologists to p rescribe th em , bec ause o f thei r contraind ica t ion wit h d r u gs such as meperi-dine. There are no litigation issues involved here. Phenel zin e su lfate was removed from the French commercial market in the 1970's b ecause of ins ufficient use by practitioners. Tranylcypromine is still commerciali zed in Fra nce but very rarely prescribed. There is, however, a new MAO inhibitor, tol o xa to ne , which has appeared on the French market in the past six yea rs and is prescribed because of its selective MAO I-A activity (11) . Toloxatone , ha s only slight and reversible tyramine potentiating effects and therefore, does not p rese n t the absolute restrictions associated with conventional MAO inhibi tors.
Polycyclic Antidepressants As noted earlier, pol ycyclic a ntidepressants in France are characteristically used for major depression ; h owe ve r , there are certain differences that should be considered. First of all , ben zodiaze pi nes are quite often combined with antidepressants during the fir st two weeks of th e rap y (16) . The rationale for this combination rests on th e co nclus io n th a t h igh le vels of anxiety during the first two weeks of treatment may contribute to su icide .
Second, an interesting practice on French inpatient units is to adm in iste r antidepressants intravenously (16) . The rationale behind this practice is the following: 1) IV infusions decrease the risk of suicide, as th e pati ent is not free to move about and leave the unit; 2) Having an IV infusion or a h eparin lock has a placebo e ffect; 3) Pharmacologically, the therapeutic lev els a re ac h ieved more rapidly, though the one to three week delay in antidepressant response is not shortened in these cases.
Third, the potentiation of the therapeutic effect of a tri cyclic a nt idepressant b y the addition of a thyroid hormone is not a common p racti ce o n French inpatient units, even though they recognize that it increases th e blood le vel of the TCA (17) . On the other hand, the addition of tryptophan to a tricycli c antidepressant is practiced (16); however, the doses of tryptophan a re ten times smaller than recommendations given in British literature ( 18, 19) .
Another association with a TCA concerns one of its a nticholinergic side effects. Orall y administered anetholtrithione co m me rcia lize d as sulfa rlem S 25 (14) , is commonl y used in France to treat dry mouth secondary to a TCA, MAOI, neuroleptic or other anticholinergic medications. In th e U.S., loca lly applied pilocarpine is theoretically recommended (2) . H ow e ve r , it is not commonl y used, given its transitory relief, the patient's eventual tol era nce , and th e temporary nature of the autonomic side effects during early stages of trea tm e nt (2) . Conversely, a product such as bethanechol, which is recommended for urinary hesitation in the U .S. (20), does not e xist in Fran ce. Acco rdi n g to Lambert (16) , urinary hesitation is related to the dose of th e drug or unde rl ying prostatic h yperthroph y, and implies that these two factors are th e o nes which sh o u ld be modified or treated to relieve the patient's discomfort.
Fourth , there does exist an antidepressant commerciali zed in Fra nce that has amphetamine-like properties, amineptine (14) , whi ch is very co m monly used in major depression with ps ychomotor retardation. Amineptine di ffers from conventional cyclic antidepressants in its dopaminergic ac t io n (it can be h ypothesized that sulpiride in low er do ses also act s as a n a ntidepressant b y th is sa me mechanism of action) (21) . Amineptine h as been comme rcial ized in Fran ce since 1978 ( 14) . The addition of amphetamine like drugs such as methylphe n id at e has been recognized in th e U .S. as an adjunct in the treat me nt o f refractory depression (2 1,22 ,2 3), as well as for treatment o f depr essio n in the elderly. St ill its e fficie ncy when used alone, is debated by certain a uthors ( 1,25, 26 ). An interesting note is that meth ylphenidate was dropped from the Fre nch comme rcial market because of its addicti ve properties (27) , a nd replaced by other drugs (fe nety lline, fenozolon e , prolintane) which are reportedl y less effec tive th erapeuticall y and have lesser sid e effects. The above perhaps e xp lains why a TCA is more commonly used in France to treat attention d efi cit di so rde r wit h hyperacti vit y in ch ild r e n as opposed to stimulant drugs.
Finally, the TCA clomipramine has long been recogni zed as indicat ed in th e treatment of obsessive compulsi ve disorder (commerciali zed in Fra nce since 1972) (14) . It is commonly used for this disorder as well as affecti ve illn ess. It just recently appeared on the U .S. market.
Antianxiety Agents
Benzodiazepines represent a class of drugs most fr equently prescr ibed in th e U.S. and France (26); however, they are not controlled subs ta nces in France (I I ) as th e y are in the U.S.A. (requiring a DEA number). Furthermo re , th e intra m uscu la r form of short-acting benzodiazapines such as lo razepam a re not available co m m e rcia lly in France; the latter is consistent wit h use of an 1M short acting neuroleptic, such as droperidol , for acute agitation . T he only in tramuscul ar ben zodiazepines available co m me r cially in France ( I I) are diazepa m and clora zepate. Their clinical indications, including alcohol d etox ificat ion , are th e sa me as in the U .S.A. Meprobamat e is sti ll commonly used in France; one of its primary indications is also alcohol d etoxification (29) .
CONCL USION
The similarities reflect that the same general gu ide lines and r u les are respected b y both countries. However, clinical ps ychopharmacological practice in the U.S . and France are quite different when one pays attention to its detail s. The relative lack of forensic considerations in France is suc h that neurol e ptics are more widely and liberally used. The absence of legal co ns trai n ts makes pol ypharmacy a more prominent issue. The simultaneous use of two or mo re neuroleptics, the common use of heptaminol for th e treatment of o rthostatic hypotension, the common use of anetholtrithione fo r t he trea tment of dry mouth a nd the use of bromocriptine for the treatment of seco ndary ga lactorr hea are all illu strations of French polypharmacy. Comme rcial factors are also a t pl a y in determining the presence or absence of a pa rti cul ar d rug a nd , the re fo re , its use in common clinical ps ych opharmacologi cal practi ce in t he respective country, making this an issue in both France and the U.S . It is in this ligh t tha t we may observe the absence of the fo llowing drugs from the U .S. market: heptam inol, anetholtrithione, sulpiride and sultopride, carpipramine, toloxatone , amineptine and valpromide to name a few. It is along this lin e of th ought that we note th e absence of buspirone, bethanechol and clozapin e fr o m th e French market.
This paper does not address in any scientific o r methodica l fashion the comparative resu lt of the different clinical psychopharmacological practices that I have outlined her e . O ne wou ld hope that awareness of th e differen ces noted, which this paper attempts to provide, will lead to further detail ed invest igat io n of the comparative results observed in both cou ntr ies . One wo uld th en hope that clinical practice would benefit from such a comparison a nd exchange of ideas.
